Skip to content

VLP Therapeutics – Imagine: Vaccines Without Borders

Search for:

Home
News
About Us
Our Science
Our Pipeline
Collaborators / Partners
Contact Us

nogretsch

About Ryota Noguchi

This author has not yet filled in any details.
So far Ryota Noguchi has created 0 blog entries.

Search for:

Popular
Recent
Comments

[News Release] VLP Therapeutics enters discussion with Nobelpharma on potential collaboration in infectious disease vaccine development and commercialization
2021.12.28
[News Release] VLPT Japan, Biken Foundation sign MoU on potential business alliance eying 2023 conclusion of “replicon” RNA COVID-19 vaccine production, sales license agreement
2023.09.14
[Preprint] Safety and immunogenicity of VLPCOV-02, a SARS-CoV-2 self-amplifying RNA vaccine with a modified base, 5-methylcytosine, in healthy individuals
2023.09.06

[Media Coverage] WIRED: “Reframing Futures of Global Health | Engineering Immunity” (Interview with Wataru Akahata)
2026.06.04
[News Release] VLP Therapeutics Japan initiates Phase 1 clinical trial of T-cell inducing COVID-19 vaccine: advancing the development of a universal vaccine against multiple SARS-CoV-2 variants
2026.03.31
[News Release] VLP Therapeutics Japan reports safety, immunogenicity, and optimal dosing of VLPCOV-02, a SARS-CoV-2 saRNA vaccine with modified 5-methylcytosine base [iScience]
2026.02.06
[News Release] VLP Therapeutics awarded US$ 2.8 million grant to develop novel malaria vaccines that improve protection, reduce costs, expand equitable access
2025.12.11
[News Release] VLPT, Boston U, NIH researchers harness 5-methylcytidine to fine-tune immune responses in replicon mRNA vaccines, paving the way for safer next-gen immunization [Science Translational Medicine]
2025.11.13
[News Release] VLP Therapeutics Teams with Swedish AI Biotech Nygen Analytics on Vinnova-Funded Cancer Immunotherapy Research
2025.11.11
[News Release] VLP Therapeutics initiates Phase 1 clinical trial of cancer treatment with Stanford Medicine: opening the door to tumor immunotherapy with VRP technology
2025.08.27
[Preprint] Alphavirus replicon particle expressing IL-12 reprograms tumor-associated macrophages and neutrophils and induces anti-tumor immunity
2025.08.12
[News release] Lyophilized SARS-CoV-2 self-amplifying RNA vaccines for microneedle Array patch delivery [Journal of Controlled Release]
2025.06.09
[News Release] VLP Therapeutics wins investment from GHIT Fund for dengue vaccine clinical trial
2025.03.17
[News Release] VLP Therapeutics makes dengue vaccine that induces antibodies, reduces replication in monkeys: Taking a step closer to next-gen dengue vaccine [Journal of Virology]
2024.04.22
[News Release] VLP Therapeutics Japan reports safety and immunogenicity of VLPCOV-02, a SARS-CoV-2 self-amplifying RNA vaccine with a modified base, 5-methylcytosine [iScience]
2024.01.23
[News Release] VLP Therapeutics Japan initiates Phase 3 clinical trial of self-amplifying “replicon” RNA COVID-19 booster targeting Omicron XBB.1.5
2023.12.28
[News Release] VLP Therapeutics group announces 3rd closing of funding to develop cancer, infectious disease vaccines; establish investigational vaccine manufacturing facility
2023.11.08
[Preprint] Incorporation of 5 methylcytidine alleviates innate immune response to self-amplifying RNA vaccine
2023.11.01
[Preprint] A Tetravalent Dengue Virus-like Particle Vaccine Induces High levels of Neutralizing Antibodies and Inhibits Dengue Replication in Non-Human Primates
2023.10.16
[News Release] VLPT Japan, Biken Foundation, Denka sign agreement to develop self-amplifying “replicon” RNA influenza vaccine
2023.09.27
[News Release] VLPT Japan, Biken Foundation sign MoU on potential business alliance eying 2023 conclusion of “replicon” RNA COVID-19 vaccine production, sales license agreement
2023.09.14
[Preprint] Safety and immunogenicity of VLPCOV-02, a SARS-CoV-2 self-amplifying RNA vaccine with a modified base, 5-methylcytosine, in healthy individuals
2023.09.06
[News Release] VLP Therapeutics group announces 2nd closing of funding to develop cancer, infectious disease vaccines, establish investigational vaccine manufacturing facility
2023.09.05

No comments have been published yet.

Recent

[Media Coverage] WIRED: “Reframing Futures of Global Health | Engineering Immunity” (Interview with Wataru Akahata)
2026.06.04
[News Release] VLP Therapeutics Japan initiates Phase 1 clinical trial of T-cell inducing COVID-19 vaccine: advancing the development of a universal vaccine against multiple SARS-CoV-2 variants
2026.03.31
[News Release] VLP Therapeutics Japan reports safety, immunogenicity, and optimal dosing of VLPCOV-02, a SARS-CoV-2 saRNA vaccine with modified 5-methylcytosine base [iScience]
2026.02.06

Home
News
- Press Release
- Publications
About Us

Our Science
Our Pipelines
Collaborators / Partners
Contact Us

Link

Facebook
Twitter
YouTube

Copyright © VLP Therapeutics. All Rights Reserved. Privacy Policy

» 日本語サイトへ

Facebook X Instagram Pinterest